Virological response and hepatocarcinogenesis in lamivudine-resistant hepatitis B virus genotype C patients treated with lamivudine plus adefovir dipivoxil

Intervirology

Volumn 51, Issue 6, 2009, Pages 385-393

  Akuta, Norio ^a   Suzuki, Fumitaka ^a   Kawamura, Yusuke ^a   Yatsuji, Hiromi ^a   Sezaki, Hitomi ^a   Suzuki, Yoshiyuki ^a   Hosaka, Tetsuya ^a   Kobayashi, Masahiro ^a   Kobayashi, Mariko ^a   Arase, Yasuji ^a   Ikeda, Kenji ^a   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

Author keywords

Adefovir dipivoxil; Basic core promoter; Core region; Hepatitis B virus; Hepatocellular carcinoma; Lamivudine; Precore

Indexed keywords

ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; LAMIVUDINE; VIRUS DNA;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONCENTRATION (PARAMETERS); DISEASE COURSE; DNA VIRUS; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INCIDENCE; JAPANESE; LIVER CARCINOMA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REGULATORY SEQUENCE; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS DETECTION; VIRUS INFECTION; VIRUS RESISTANCE;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; JAPAN; LAMIVUDINE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

EID: 60449105586     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000203283     Document Type: Article

References (35)

1. Wright TL, Lau JY: Clinical aspects of hepatitis B virus infection. Lancet 1993; 342: 1340-1344.
2. Ganem D, Prince AM: Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004; 350: 1118-1129.
3. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Man RA, Thomas HC: Lamivudine therapy for chronic hepatitis B: a six-month randomized doseranging study. Gastroenterology 1997; 113: 1258-1263.
4. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF: A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339: 61-68.
5. Suzuki Y, Kumada H, Ikeda K, Chayama K, Arase Y, Saitoh S, Tsubota A, Kobayashi M, Koike M, Ogawa N, Tanikawa K: Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol 1999; 30: 743-748.
6. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown NA: A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigenpositive chronic hepatitis B. Gastroenterology 2005; 129: 528-536.
7. Van Bömmel F, Zöllner B, Sarrazin C, Spengler U, Hüppe D, Möller B, Feucht HH, Wiedenmann B, Berg T: Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325.
8. Liaw YF, Sung JJY, Chow WC, Farrell G, Lee CZ, Yuen HY, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531.
9. Matsumoto A, Tanaka E, Rokuhara A, Kiyosawa K, Kumada H, Omata M, Okita K, Hayashi N, Okanoue T, Iino S, Tanikawa K: Efficacy of lamivudine for preventing hepatocellular carcinoma in chronic hepatitis B: a multicenter retrospective study of 2,795 patients. Hepatol Res 2005; 32: 173-184.
10. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD: Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 1670-1677.
11. Delaney WE 4th, Yang H, Westland CE, Das K, Arnold E, Gibbs CS, Miller MD, Xiong S: The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol 2003; 77: 11833-11841.
12. Sherman M, Yurdaydin C, Sollano J, Silva M, Liaw YF, Cianciara J, Boron-Kaczmarska A, Martin D, Goodman Z, Colonno R, Cross A, Denisky G, Kreter B, Hindes R: Entecavir for treatment of lamivudine-refractory, HBeAgpositive chronic hepatitis B. Gastroenterology 2006; 130: 2039-2049.
13. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ: Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B. Hepatology 2007; 45: 307-313.
14. Hosaka T, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Someya T, Sezaki H, Akuta N, Tsubota A, Arase Y, Ikeda K, Kumada H: Adefovir dipivoxil for treatment of breakthrough hepatitis caused by lamivudine-resistant mutants of hepatitis B virus. Intervirology 2004; 47: 362-369.
15. Tong SP, Li JS, Vitvitski L, Trepo C: Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology 1992; 191: 237-245.
16. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriya K, Tanaka T, Miyakawa Y, Mayumi M: Hepatitis B virus with mutations in the core promoter for an e antigennegative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102- 8110.
17. Laskus T, Rakela J, Tong MJ, Nowicki MJ, Mosley JW, Persing DH: Naturally occurring hepatitis B virus mutants with deletions in the core promoter region. J Hepatol 1994; 20: 837-841.
18. Laskus T, Rakela J, Nowicki MJ, Persing DH: Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B. Gastroenterology 1995; 109: 1618-1623.
19. Takahashi K, Aoyama K, Ohno N, Iwata K, Akahane Y, Baba K, Yoshizawa H, Mishiro S: The precore/core promoter mutant (T1762/ A1764) of hepatitis B virus: clinical significance and an easy method for detection. J Gen Virol 1995; 76: 3159-3164.
20. Lindh M, Horal P, Dhillon AP, Furuta Y, Norkrans G: Hepatitis B virus carriers without precore mutations in hepatitis B e antigen- negative stage show more severe liver damage. Hepatology 1996; 24: 494-501.
21. Erhardt A, Reineke U, Blondin D, Gerlich WH, Adams O, Heintges T, Niederau C, Häussinger D: Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B. Hepatology 2000; 31: 716-725.
22. Usuda S, Okamoto H, Iwanari H, Baba K, Tsuda F, Miyakawa Y, Mayumi M: Serological detection of hepatitis B virus genotypes by ELISA with monoclonal antibodies to type-specific epitopes in the preS2-region product. J Virol Methods 1999; 80: 97-112.
23. Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, Mayumi M: Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol 1988; 69: 2575- 2583.
24. Kwok S, Higuchi R: Avoiding false positive with PCR. Nature 1989; 339: 237-238.
25. Desmet VJ, Gerber M, Hoofnagle JH, Manna M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-1520.
26. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M: Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudineresistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451.
27. Kobayashi M, Ikeda K, Hosaka T, Sezaki H, Someya T, Akuta N, Suzuki F, Suzuki Y, Saitoh S, Arase Y, Miyakawa Y, Kumada H: Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J Med Virol 2006; 78: 459- 465.
28. Bréchot C, Pourcel C, Louise A, Rain B, Tiollais P: Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Na - ture 1980; 286: 533-535.
29. Bréchot C, Hadchouel M, Scotto J, Fonck M, Potet F, Vyas GN, Tiollais P: State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases. Proc Natl Acad Sci USA 1981; 78: 3906-3910.
30. Shafritz DA, Shouval D, Sherman HI, Hadziyannis SJ, Kew MC: Integration of hepatitis B virus DNA into the genome of liver cells in chronic liver disease and hepatocellular carcinoma. Studies in percutaneous liver biopsies and post-mortem tissue specimens. N Engl J Med 1981; 305: 1067-1073.
31. Wong DK, Yuen MF, Poon RT, Yuen JC, Fung J, Lai CL: Quantification of hepatitis B virus covalently closed circular DNA in patients with hepatocellular carcinoma. J Hepatol 2006; 45: 553-559.
32. Wursthorn K, Lugehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J: Peginterferon- -2 b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684.
33. Wong DK, Yuen MF, Ngai VW, Fung J, Lai CL: One-year entecavir and lamivudine therapy results in reduction of hepatitis B virus intrahepatic convalently closed circular DNA levels. Antivir Ther 2006; 11: 909-916.
34. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF: Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971- 975.
35. Lin SM, Yu ML, Lee CM, Chien RN, Sheen IS, Chu CM, Liaw YF: Interferon therapy in HBeAg-positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52.